PDF(432 KB)
Repeated yellowing of the skin and sclera for 2 years
YUAN Xiao-Ye, HE Xiang-Ling, ZOU Hui, ZOU Run-Ying
Chinese Journal of Contemporary Pediatrics ›› 2017, Vol. 19 ›› Issue (1) : 77-80.
PDF(432 KB)
PDF(432 KB)
Repeated yellowing of the skin and sclera for 2 years
Objective A two-year-old girl was admitted due to repeated yellowing of the skin and sclera for 2 years and had no other specific symptoms or signs. The use of phenobarbital could relieve the symptoms of jaundice. Multiple examinations showed increased indirect bilirubin levels, and the results of aminotransferases and liver imaging were normal. There was no evidence of hemolysis. The analysis of UGT1A1 gene in her family found that this child had double homozygous mutation of c.211G > A (G71R) and c.1456T > G (Y486D), which had been reported as the pathogenic mutation for Gilbert syndrome. Her parents carried double heterozygous mutation of G71R and Y486D and had no symptom of jaundice. The child was diagnosed as having Gilbert syndrome. It is concluded that as for patients with unconjugated hyperbilirubinemia which cannot be explained by liver damage and hemolysis, their family history should be investigated in detail and gene analysis should be performed as early as possible, in order to identify congenital bilirubin metabolic disorders.
Gilbert syndrome / Jaundice / UGT1A1 gene / Gene mutation / Child
[1] Maruo Y, Nakahara S, Yanagi T, et al. Genotype of UGT1A1 and phenotype correlation between Crigler-Najjar syndrome type Ⅱ and Gilbert syndrome[J]. J Gastroenterol Hepatol, 2016, 31(2):403-408.
[2] Fretzayas A, Moustaki M, Liapi O, et al. Gilbert syndrome[J]. Europ J Pediatr, 2012, 171(1):11-15.
[3] Maruhashi T, Soga J, Fujimura N, et al. Hyperbilirubinemia, augmentation of endothelial function, and decrease in oxidative stress in Gilbert syndrome[J]. Circulation, 2012, 126(5):598-603.
[4] Radlovi? N. Hereditary hyperbilirubinemia[J]. Srp Arh Celok Lek, 2014, 142(3-4):257-260.
[5] 张玉喜, 马晓瑞, 马国仁. Gilbert综合征21例临床分析[J]. 宁夏医学杂志, 2010, 32(7):634-635.
[6] 任东青, 黄晓峰, 尹文, 等. Gilbert综合征肝活检的超微结构特征[J]. 现代生物医学进展, 2012, 18(12):3439-3441.
[7] Hallal H, Egea JM, Mas P, et al. A shortened, 2-hour rifampin test:a useful tool in Gilbert's syndrome[J]. J Gastroenterol Hepatol, 2006, 29(2):63-65.
[8] Weiß J. The Crigler-Najjar syndrome[J]. Z Gastroenterol, 2014, 52(4):338.
[9] Ostanbek B, Furlan D, Bratani? B. Genotyping UGT1A1(TA)(n) polymorphism rare variants by high resolution melting curve analysis[J]. Clin Chim Acta, 2011, 412(5-6):489-490.
[10] Canu G, Minucci A, Zuppi C, et al. Gilbert and Crigler Najjar syndromes:an update of the UDP-glucuronosyltransferase 1A1(UGT1A1) gene mutation database[J]. Blood Cells Mol Dis, 2013, 50(4):273-280.
[11] Costa E, Vieira E, Dos SR. The polymorphism C.-3279> G in the phenobarbital-responsive enhancer module of the bilirubin UDP-glucuronosyltransferase gene is associated with gilbert syndrome[J]. Clin Chem, 2005, 51(11):2204-2206.
[12] 沈健, 吴建新, 李定国. 1例中国Gilbert综合征家系UGT1A1基因遗传分析[J]. 胃肠病学, 2007, 7(12):392-396.
[13] Ralotychou V, Karakosta M, Tzanetea R, et al. Contribution of G71R mutation to Gilbert's syndrome phenotype in a Greek patient:A case report[J]. World J Gastrointest Pharmacol Ther, 2011, 2(5):42-45.
[14] Yamamoto K, Sato H, Fujiyama Y, et al. Contribution of two missense mutations (G71R and Y486D) of the bilirubin UDP glycosyltransferase(UGT1A1) gene to phenotypes of Gilbert's syndrome and Crigler-Najjar syndrome type Ⅱ[J]. Biochim Biophys Acta, 1998, 1406(3):267-273.
[15] 余利红, 高静, 王春丽, 等. 一个中国Gilbert综合征家系的遗传学分析[J]. 遗传, 2006, 28(1):11-16.
[16] 姚光弼. 遗传性高胆红素血症[M]//姚光弼.临床肝脏病学. 第2版.上海:上海科学技术出版社, 2011:502-506.
[17] Ko JS, Chang JY, Moon JS, et al. Molecular analysis of the UGT1A1 gene in Korean patients with Crigler-Najjar syndrome type Ⅱ[J]. Pediatr Gastroenterol Hepatol Nutr, 2014, 17(1):37-40.
[18] Memon N, Weinberger BI, Hegyi T, et al. Inherited disorders of bilirubin clearance[J]. Pediatr Res, 2016, 79(3):378-386.
[19] Oda S, Fujiwara R, Kutsuno Y, et al. Targeted screen for human UDP glucuronosyltransferases inhibitors and the evaluation of potential drug-drug interactions with zafirlukast[J]. Drug Metab Dispos, 2015, 43(6):812-818.
